Stay updated with breaking news from Gerry Proehl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track -- Dermata continues discussions with potential botulinum toxin partners for DMT410 -- Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis -SAN DIEGO, CA / ACCESSWIRE / May 15, 202...
- Dermata to provide a corporate update followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic...
Dermata to Present at the Emerging Growth Conference on February 7, ...
Dermata Therapeutics, Inc.
Dermata Therapeutics Inc (NASDAQ: DRMA) stock was trading higher Friday after the company announced the issuance of a new patent in Japan for its